Contrasting Collegium Pharmaceutical (COLL) and The Competition

Collegium Pharmaceutical (NASDAQ: COLL) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Collegium Pharmaceutical to related businesses based on the strength of its analyst recommendations, profitability, dividends, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

This table compares Collegium Pharmaceutical and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Collegium Pharmaceutical $7.44 million -$97.95 million -2.72
Collegium Pharmaceutical Competitors $8.20 billion $2.68 billion -0.88

Collegium Pharmaceutical’s peers have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

83.0% of Collegium Pharmaceutical shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.8% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Collegium Pharmaceutical has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s peers have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Collegium Pharmaceutical and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical 0 0 5 0 3.00
Collegium Pharmaceutical Competitors 837 3752 6776 185 2.55

Collegium Pharmaceutical presently has a consensus target price of $20.00, indicating a potential upside of 101.21%. As a group, “Pharmaceuticals” companies have a potential upside of 27.83%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than its peers.

Profitability

This table compares Collegium Pharmaceutical and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical -1,319.39% -93.73% -74.81%
Collegium Pharmaceutical Competitors -2,859.64% -67.98% -9.26%

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply